Cart
sales@molnova.com
methyl 2-hydroxy-4-methylvalerate
CAS No. 40348-72-9
methyl 2-hydroxy-4-methylvalerate( —— )
Catalog No. M28725 CAS No. 40348-72-9
Methyl 2-hydroxy-4-methylvalerate is one of dominant volatile compounds in Zhenjiang aromatic vinegar.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 25MG | 34 | In Stock |
|
| 50MG | 47 | In Stock |
|
| 100MG | 67 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namemethyl 2-hydroxy-4-methylvalerate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethyl 2-hydroxy-4-methylvalerate is one of dominant volatile compounds in Zhenjiang aromatic vinegar.
-
DescriptionMethyl 2-hydroxy-4-methylvalerate is one of dominant volatile compounds in Zhenjiang aromatic vinegar.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptortumor-associated macrophages (TAMs)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number40348-72-9
-
Formula Weight146.186
-
Molecular FormulaC7H14O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (684.09 mM)
-
SMILESCOC(=O)C(O)CC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pei H, et al. iscovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. Eur J Med Chem. 2019 Sep 28;183:111741.
molnova catalog
related products
-
Alisol C
Alisol C can improve glucose uptake in Hep G2 cells, it may be one of the therapeutic material basis in hypoglycemic activities in A. orientalis. Alisol C,16,23-oxido-alisol B and alisol O in Zexie may cause nephrotoxicity.
-
Pedunculoside
Pedunculoside is extracted from Ilex rotunda Thunb.
-
Dermatan sulphate so...
Dermatan sulphate sodium, a glycosaminoglycan and thrombin inactivator, exhibits antithrombotic activity by selectively catalyzing the inactivation of thrombin via heparin cofactor II, without interaction with antithrombin III.
